Background And Study Aims: Appendiceal neuroendocrine neo-plasms (aNENs) are a diverse group of malignant neoplasms of varying biological behavior for which information about manage-ment and outcome is sparse, with the majority of available studies being retrospective, including only a limited number of patients, and therefore not necessarily reflecting the reality in the community. In the present study clinical, epidemiological and pathological data of appendiceal neuroendocrine neoplasms in Belgium is provided and compared with current literature.

Methods: A population-based study was conducted by linking data of the Belgian Cancer Registry with medical procedures in the Belgian Health Insurance database for patients diagnosed with aNEN between 2010 and 2015.

Results: We found an aNEN incidence of 0.97/100.000 person years in Belgium. Neuroendocrine carcinoma of the appendix are rare. Most appendiceal neuroendocrine tumors (aNETs) are small G1 tumors. Positive lymph nodes are often found in tumors larger than 2cm, especially aNET G2.

Conclusion: A rapid uptake of changing classifications was seen in the community. However, systematic reporting of risk factors for small aNEN can still be improved and should be stimulated. In 9% of cases, reclassifications had to be made, pointing out that in a retrospective analysis, original pathological reports should be checked for specific parameters, before reliable conclusions can be drawn.

Download full-text PDF

Source
http://dx.doi.org/10.51821/84.3.011DOI Listing

Publication Analysis

Top Keywords

appendiceal neuroendocrine
16
neuroendocrine neoplasms
8
belgian cancer
8
cancer registry
8
neuroendocrine
5
lessons learned
4
appendiceal
4
learned appendiceal
4
neoplasms data
4
data analysis
4

Similar Publications

Purpose: Neuroendocrine neoplasms of the appendix (aNET) are rare tumors that are often diagnosed by pathology as an incidental finding after appendectomy for acute appendicitis. Several guidelines proposed risk criteria to indicate oncological completion surgery after appendectomy. The aim of this study was to evaluate the reliability of proposed criteria for completion surgery of aNET.

View Article and Find Full Text PDF
Article Synopsis
  • National guidelines recommend segmental colectomy for appendiceal neuroendocrine neoplasms larger than 2.0 cm due to risks of lymph node involvement, with conditional overall survival becoming an important prognostic tool.
  • A study of 3,541 patients revealed that 16% had positive lymph nodes, and factors like size, depth of invasion, and lymphovascular involvement were correlated with metastasis.
  • The findings suggest that more clinicopathologic factors should influence decisions on surgical treatment and surveillance for better survival rates, especially for patients with more aggressive histologies.
View Article and Find Full Text PDF

Background/aim: Appendiceal neuroendocrine tumors (ANETs) are the most prevalent type of appendiceal neoplasm and the fifth most common neuroendocrine tumor in the gastrointestinal tract. In this study, we described the clinicopathological features of patients with ANET.

Patients And Methods: We reviewed the clinicopathological findings and histopathological reports of six patients diagnosed with ANET between January 2014 and December 2023 at Korea University Medical Center, Anam Hospital.

View Article and Find Full Text PDF

Background: Neuroendocrine tumors (NETs) of the appendix are typically detected incidentally during appendectomy. Recent studies reported no metachronous metastases among patients with primary tumors <2 cm, regardless of lymph node status or referral for completion hemicolectomy. However, questions persist regarding the possibility of metastases developing decades after surgical resection, particularly because appendiceal NETs are frequently diagnosed in young adults and children.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!